Skip to content

Novel Palliative Care Model for Advanced Cancer Patients: A Randomized Controlled Trial Study

Novel Palliative Care Model for Advanced Cancer Patients: A Randomized Controlled Trial Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04242251
Acronym
SPARKLE2
Enrollment
239
Registered
2020-01-27
Start date
2021-02-08
Completion date
2024-01-31
Last updated
2024-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Palliative Care, Cancer, Health Services Research

Brief summary

This is a randomized controlled trial of the 'Supportive and Palliative care Review Kit in Locations Everywhere' (SPARKLE) intervention, an outpatient-based model of early palliative care. The SPARKLE intervention comprises regular symptom monitoring using questionnaires, early identification and prompt treatment of problems identified. Proactive screening for problems facilitates earlier palliative care interventions for advanced cancer patients, whenever needs arise.

Detailed description

This is a randomized controlled trial to compare clinical outcomes between advanced cancer patients receiving and not receiving care from the SPARKLE care model, in addition to current oncologic-led palliative care model. The hypothesis is that the SPARKLE care model results in a) improved quality of life of both advanced cancer patients and their caregivers, and b) reduced acute healthcare utilization and costs by these patients. Primary Study Aim: To determine the incremental effect of SPARKLE in addition to usual oncologist-led care on quality of life of advanced cancer patients. Patients' quality of life will be measured at baseline before randomization and 16 weeks after randomization using the Functional Assessment of Cancer Therapy - General (FACT-G). Secondary Study Aim 1: To determine the incremental effect of SPARKLE in addition to usual oncologist-led care on caregivers' quality of life. Caregiver quality of life will be measured at baseline before randomization and 16 weeks after randomization using the Singapore Caregiver Quality of Life Scale (SCQOLS), which was validated among caregivers of advanced cancer patients in Singapore.17 The PI was part of the team, led by the applicant's mentor, that developed the SCQOLS. Secondary Study Aim 2: To determine the effect of SPARKLE in addition to usual oncologist-led care on healthcare utilization and total healthcare costs, including the costs of delivering SPARKLE, from randomization until death. Healthcare utilization and cost data will be extracted from medical and billing data. SPARKLE costs will be captured prospectively using an Activity Based Costing Approach. The study hypothesis is that per capita healthcare costs will be lower in the SPARKLE model due to fewer admissions and shorter hospital lengths of stay when admitted. A prospective randomized controlled trial design will be used to test the effectiveness of the SPARKLE model. The recruitment target is 240 patients with advanced cancers, defined as stage 4 solid tumors including lung, colorectal, nasopharyngeal and pancreatic cancers. Eligible participants are randomized to usual care or SPARKLE intervention group using randomized permuted blocks method generated by an independent statistician, with block size kept unknown to the clinical investigators/site personnel. A total of 240 caregivers will be recruited. The study will take place in the National Cancer Centre of Singapore (NCCS).

Interventions

OTHERSPARKLE Model of care

Patients will receive the SPARKLE model of care in addition to usual oncologist-led care. The SPARKLE model will be led by a palliative medicine doctor and administered by nurses and staff without specific nursing or medical training. It utilizes a stepped care approach where all patients will initially have low-intensity model focused on weekly symptom monitoring through a patient-reported questionnaire. If any problems are identified, then patients step up to a higher-intensity care model where a nurse will conduct a phone assessment of the symptom problems. If the presence of symptoms is confirmed, patients step up again to an even higher-intensity care model where treatment of symptoms will be initiated by the SPARKLE nurse, depending on the severity of the problems. If the symptoms are not fully resolved, the patients will then step up to the highest-intensity care model which is an existing palliative care service- either palliative care outpatient clinic or home hospice.

Sponsors

Ministry of Health, Singapore
CollaboratorOTHER_GOV
National Cancer Centre, Singapore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Masking description

The person administering the patient reported outcome measures will be blinded to the participant's allocation to study arms.

Eligibility

Sex/Gender
ALL
Age
21 Years to 120 Years
Healthy volunteers
Yes

Inclusion criteria

Patient participants Inclusion Criteria: * Adult aged 21 and above * Stage 4 solid tumor Patient participants

Exclusion criteria

* Unable to complete patient-reported outcome measures * Already under the care of an existing palliative care service Caregiver participants Inclusion Criteria: \- Adult aged 21 and above Caregiver participants

Design outcomes

Primary

MeasureTime frameDescription
Functional Assessment of Cancer Therapy- General16 weeksQuality of life is scored on a scale of 0 to 108, with higher scores indicating better outcomes

Secondary

MeasureTime frameDescription
Singapore Caregiver Quality of Life Scale16 weeksCaregiver quality of life is scored on a scale of 0 to 100, with higher scores indicating better outcomes

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026